Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.47 (1y: -17%)
Market Cap 31.4 M P/E(ttm)
Enterprise Value P/B
DXR- AMEX (USA)
Daxor Corporation
Not Rated
Top Ranked Predictable Companies
$7.47
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
» DXR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

DXR Guru Trades in Q2 2012

Jim Simons 47,800 sh (-0.62%)
» More
Q3 2012

DXR Guru Trades in Q3 2012

Jim Simons 48,000 sh (+0.42%)
» More
Q4 2012

DXR Guru Trades in Q4 2012

Jim Simons 48,000 sh (unchged)
» More
Q1 2013

DXR Guru Trades in Q1 2013

Jim Simons 48,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DXR



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/S 21.70
DXR's P/S is ranked lower than
96% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. DXR: 21.70 )
DXR' s 10-Year P/S Range
Min: 0   Max: 0
Current: 21.7
EV-to-EBIT 10.9
DXR's EV-to-EBIT is ranked lower than
66% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. DXR: 10.9 )
DXR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 10.9

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.70
DXR's Dividend Yield is ranked higher than
95% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. DXR: 2.70 )
DXR' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 2.7
Yield on cost (5-Year) 2.70
DXR's Yield on cost (5-Year) is ranked higher than
91% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. DXR: 2.70 )
DXR' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 2.7

Valuation & Return

vs
industry		 vs
history

Business Description

Daxor Corporation was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
» More Articles for DXR

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR Feb 10 2013 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2010 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2010 
Daxor Corp Reports Operating Results (10-Q) May 11 2010 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2009 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2009 
Daxor Corp Reports Operating Results (10-Q) May 12 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial